Chongqing Zhengchuan Pharmaceutical Packaging Co.Ltd(603976) april 25 announced the 2021 annual report and the first quarterly report of 2022 at the same time. Last year, the company achieved an operating revenue of 797 million yuan, a year-on-year increase of 58.70%; The net profit attributable to the parent company was 107 million yuan, a substantial increase of 100.95% year-on-year; The net profit after deducting non profit was 924493 million yuan, an increase of 96.11%, and the earnings per share was 0.71 yuan. The company’s profit distribution plan for the 21st year is 3.08 yuan (including tax) per 10 shares, and the cash dividend ratio is 43.69%.
From January to March this year, the company’s performance continued to maintain rapid growth, realizing an operating revenue of 225 million yuan, a year-on-year increase of 44.26%; The net profit attributable to the parent company was 258978 million yuan, a year-on-year increase of 30.72%; The net profit after deducting non profit was RMB 218853 million, with an increase of 29.95% and earnings per share of RMB 0.17.
It is understood that in 2021, the company took the improvement of capacity as the main line, took the innovation drive as the development initiative, accelerated the “transformation and upgrading” of product structure, strengthened the layout of medium and high-end products, focused on promoting project construction and capacity expansion, continued to improve and upgrade technology, continued to promote production quality and efficiency, and carried out a series of organizational and management changes, The overall profitability and sustainable development ability of the company have been significantly enhanced.
During the reporting period, the company’s market expansion of high-end pharmaceutical packaging materials reached a new level, established comprehensive strategic cooperative relations with many well-known pharmaceutical enterprises, and continuously expanded the customer base of medium and high-end products; Accelerate the construction of pre potting syringe product production line, constantly meet the new needs of the market and customers, and improve the competitiveness of products; The first medium boron kiln has successfully reached the production capacity and achieved efficiency, realizing the integrated large-scale production of “independent medium boron tube drawing – medium boron bottle making”, and the production capacity and technical level have reached the industry leading level, which can fully meet the market demand for medium boron product increment and high-end packaging materials such as vaccines and biological products under the consistency evaluation, and the second medium boron kiln construction project has been started. In addition, the company has also set up a number of overseas sales platforms, and certain progress has been made in the layout of the main target markets, laying the foundation for the later international market expansion.
Looking forward to 2022, Chongqing Zhengchuan Pharmaceutical Packaging Co.Ltd(603976) said that under the guidance of the idea of “consolidating the operation and management mode, paying close attention to new products and technologies, and rapidly improving the market influence”, it would seize the market and industry opportunity of product upgrading, accelerate the comprehensive layout of China boron product market, fully promote the in-depth cooperation with key strategic customers, and constantly consolidate the foundation of the company’s products in the high-end pharmaceutical packaging material market; We will continue to improve the large-scale production capacity and technical competitiveness of China boron glass tubes, fully promote the construction of raised investment projects, formulate systematic marketing strategies, and further improve the sustainable comprehensive profitability.
According to the 2022 financial budget report prepared by the company, the company is expected to achieve an operating revenue of 900 million yuan and a net profit of 90 million yuan.
